NCT02577250View on ClinicalTrials.gov

Ketamine Infusions for PTSD and Treatment-Resistant Depression

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Depressive Disorder, Treatment-ResistantStress Disorders, Post-Traumatic
Interventions
DRUG

Ketamine

Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.

Trial Locations (1)

55417

Minneapolis Va Health Care System, Minneapolis MN, Minneapolis

All Listed Sponsors
lead

Minneapolis Veterans Affairs Medical Center

FED

NCT02577250 - Ketamine Infusions for PTSD and Treatment-Resistant Depression | Biotech Hunter | Biotech Hunter